Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Myeloid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 34Urinary Bladder Neoplasms 29Neoplasm Metastasis 20Lung Neoplasms 19Ovarian Neoplasms 18Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Neoplasms 13Nasopharyngeal Carcinoma 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Recurrence 9Fallopian Tube Neoplasms 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Hodgkin Disease 4Colonic Neoplasms 4

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 5Nivolumab 5selpercatinib 4Iodine-124 4Biopsy 4binimetinib 3Iodine-131 3Cetuximab 3ulixertinib 2trametinib 2pembrolizumab 2omipalisib 2larotrectinib 2defactinib 2dabrafenib 2Surveys and Questionnaires 2Sunitinib 2Radiosurgery 2Ipilimumab 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tipifarnib 1temsirolimus 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Gemcitabine × 90 days × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡